Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
|---|---|---|---|---|---|---|---|---|---|---|
| PDXHCI002 | Taxol | Chemo | Chemotherapy | 0.0024935 | -0.5117 | 0.9207 | 0.3881 | 2.7479 | 0.0031656 | 0.99139 |
| PDXHCI002 | Topotecan | Topo I | Chemotherapy | 0.0066461 | -0.7006 | 1.0199 | 0.1157 | 0.8130 | 0.015555 | 0.94766 |
| PDXHCI002 | Etoposide | Topo II | Chemotherapy | 0.18199 | -0.1795 | 0.4902 | -0.0311 | 1.1589 | 0.23962 | 0.98993 |
| PDXHCI002 | Dasatinib | BCR/ABL | MAPK/nRTK | 0.50855 | 0.0322 | 0.3757 | 0.0065 | 0.4070 | 3.0924 | 0.95256 |
| PDXHCI002 | Trametinib | MEK | MAPK/nRTK | Inf | 0.6425 | 0.1995 | 0.0041 | 1.2187 | 0.0050548 | 0.98796 |
| PDXHCI002 | Saracatinib | SRC | MAPK/nRTK | 0.080448 | 0.0015 | 0.5120 | 0.0185 | 0.6754 | 0.078329 | 0.98663 |
| PDXHCI002 | ABT-737 | Bcl2/XL | Misc | 5.6112 | 0.1456 | 0.0694 | 0.0306 | 1.3811 | 12.4316 | 0.97863 |
| PDXHCI002 | Vorinostat | HDAC | Misc | 0.28215 | -0.5830 | 0.5449 | 0.2572 | 1.5567 | 0.47533 | 0.99111 |
| PDXHCI002 | Luminespib | HSP90 | Misc | 0.0043954 | -0.2805 | 0.7099 | 0.1525 | 3.6850 | 0.0049332 | 0.9976 |
| PDXHCI002 | A-1210477 | Mcl-1 | Misc | Inf | 0.9814 | -0.0380 | 0.0049 | 0.0000 | Inf | -2.2577 |
| PDXHCI002 | Olaparib | PARP | Misc | 3.9307 | 0.2648 | 0.1679 | 0.0173 | 0.5697 | 27.0413 | 0.98896 |
| PDXHCI002 | Bleomycin | Radiation | Misc | 1.1636 | -0.1199 | 0.2715 | -0.0373 | 0.9659 | 2.0671 | 0.9892 |
| PDXHCI002 | Ipatasertib | AKT | PI3K/mTOR | Inf | 1.0500 | -0.0488 | -0.0112 | 0.0000 | Inf | -59.6281 |
| PDXHCI002 | Alpelisib | PI3Ka | PI3K/mTOR | 30.4631 | 0.6296 | 0.0630 | -0.0034 | 0.7047 | 10.7379 | 0.92415 |
| PDXHCI002 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 0.6002 | -0.1369 | 0.3740 | 0.0320 | 0.4025 | 9.1998 | 0.95462 |
| PDXHCI002 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.8545 | -0.0204 | -0.0045 | 5.0000 | 4.5889 | 0.61889 |
| PDXHCI002 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.12881 | -0.1017 | 0.2036 | 0.0001 | 1.3377 | 0.15771 | 0.9736 |
| PDXHCI002 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.9869 | -0.0453 | -0.0479 | 0.0000 | Inf | -4.5815 |
| PDXHCI002 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.20621 | 0.2290 | 0.2366 | -0.0367 | 1.3099 | 0.11357 | 0.97533 |
| PDXHCI002 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 0.8732 | -0.0268 | -0.0011 | 0.0000 | Inf | 0.45924 |
| PDXHCI002 | Buparlisib | pan PI3K | PI3K/mTOR | 1.4379 | -0.4797 | 0.2447 | 0.1228 | 3.2385 | 1.7721 | 0.99509 |
| PDXHCI002 | Pictilisib | pan PI3K | PI3K/mTOR | 2.2488 | -0.0101 | 0.2122 | 0.0264 | 0.6580 | 11.9412 | 0.96622 |
| PDXHCI002 | Ceritinib | ALK | RTK | 0.33749 | -0.6341 | 0.5101 | 0.1873 | 1.5133 | 0.59866 | 0.99609 |
| PDXHCI002 | Neratinib | EGFR/HER2 | RTK | 0.16177 | -0.1614 | 0.3672 | 0.0401 | 0.5156 | 0.9064 | 0.97354 |
| PDXHCI002 | Tivantinib | MET | RTK | 0.23837 | -0.4868 | 0.5347 | 0.2564 | 2.4382 | 0.31389 | 0.99794 |